Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 73Neoplasm Metastasis 30Kidney Neoplasms 26Neoplasms 19Breast Neoplasms 14Prostatic Neoplasms 12Urinary Bladder Neoplasms 10Melanoma 9Gastrointestinal Stromal Tumors 9Brain Neoplasms 9Glioblastoma 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 7Liver Neoplasms 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Esophageal Neoplasms 5Colorectal Neoplasms 5Thyroid Neoplasms 4Solid Tumors 4Osteosarcoma 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Adenocarcinoma 4Uveal Melanoma 3Thymoma 3Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Docetaxel 3Prednisone 2sargramostim 1epothilone B 1cabazitaxel 1Sunitinib 1PE regimen 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Refractory Prostate Cancer × Sunitinib × Clear all
NCT00795171 2010-08-18

Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer

Medical University of Vienna

Phase 2 Unknown
60 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡